Harel Insurance Investments & Financial Services Ltd. Trims Holdings in Urogen Pharma $URGN

Harel Insurance Investments & Financial Services Ltd. decreased its holdings in shares of Urogen Pharma (NASDAQ:URGN) by 47.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 82,772 shares of the company’s stock after selling 75,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. owned approximately 0.18% of Urogen Pharma worth $1,651,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its stake in shares of Urogen Pharma by 347.5% in the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company’s stock valued at $1,262,000 after purchasing an additional 88,577 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock valued at $258,000 after buying an additional 1,653 shares during the last quarter. Jane Street Group LLC grew its position in Urogen Pharma by 94.3% in the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company’s stock valued at $566,000 after buying an additional 24,839 shares during the last quarter. Truist Financial Corp acquired a new position in Urogen Pharma in the 2nd quarter valued at $423,000. Finally, Bender Robert & Associates purchased a new position in Urogen Pharma during the 2nd quarter worth $475,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on URGN shares. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Urogen Pharma in a research note on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. Wall Street Zen raised Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, D. Boral Capital restated a “buy” rating and issued a $33.00 price target on shares of Urogen Pharma in a research note on Monday, January 5th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Urogen Pharma presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.00.

Insider Activity at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the insider directly owned 139,025 shares of the company’s stock, valued at approximately $3,475,625. This represents a 6.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.70% of the stock is owned by corporate insiders.

Urogen Pharma Trading Down 3.8%

URGN stock opened at $18.80 on Monday. The company has a market cap of $880.03 million, a price-to-earnings ratio of -5.43 and a beta of 1.29. The firm has a 50 day moving average of $23.58 and a 200-day moving average of $20.10. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $30.00.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.03. The firm had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. Sell-side analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.